Norman Wolmark, the chairman of oncology at Allegheny General Hospital in Pittsburgh, unveiled the results in a presentation that dripped with sarcasm.

FORBES: How The FDA Tripped Bristol-Myers Squibb

Allegheny General Hospital's Norman Wolmark, who conducted the trial, said the researchers found no evidence that Avastin was inducing faster or broader spread.

FORBES: Questions Swirl Around Avastin

"The differences that we're seeing there are among the greatest that I have seen for years and years and years, " says Norman Wolmark of Pittsburgh's Allegheny General Hospital, in response to the Herceptin results.

FORBES: Genentech's Triumph

Wolmark said he felt "dysphoria" presenting positive results for a drug that had never reached the market in the U.S., and joked that U.S. oncologists could simply forget about the data after he had presented them.

FORBES: How The FDA Tripped Bristol-Myers Squibb

"It's been twenty years since famous names had their faces on the cover of Time magazine saying this would be the magic bullet, " says Norman Wolmark Chairman of Oncology at Allegheny General Hospital in Pittsburgh and an investigator in a trial testing Eloxatan.

FORBES: Big Pharma Could Hog Biotech's Spotlight